Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies

NCT01226316 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01226316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01226316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
December 1, 2010
Completion date
December 3, 2024
Enrollment
285 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic breast cancer, advanced solid malignancy, akt1, cervical cancer, endometrial cancer, er positive, her2 positive, ovarian cancer, pharmacodynamics, pharmacokinetics, pik3ca, pten, safety and tolerability, tumour response